Clinical Notes AI's AI-powered platform uses over 25 different AI models to generate highly complex behavioral healthcare ...

The company's CEO, James Dentzer, expressed optimism about the progress of Curis's clinical programs and the ... emavusertib. In terms of analyst ratings, H.C. Wainwright adjusted its outlook ...

Yaron Werber has given his Buy rating due to a combination of factors, primarily the promising progress and outcomes of IO Biotech’s clinical trials. The company’s Phase 3 melanoma study is on ...

presented to its investors. Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing precision oncology medicines using its proprietary Acrivon ...

Unfortunately, I don’t see major near-term catalysts that could justify a bullish rating at this stage. Similarly, by the ...

GE HealthCare's AI initiatives, including AI-powered imaging solutions and strategic partnerships, are led by its chief AI ...

The company reported a strong cash position, which is expected to fund operations into late 2026, and emphasized the progress made in its clinical programs, including the completion of enrollment ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Note that this webcast is being recorded at the ... Throughout the third quarter, we have made solid progress with the ...

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial ...

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal ...